NCT07260708 2025-12-19
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
Clinical Trials
21 trialsNCT06649656 2024-10-21
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT06413953 2024-07-03
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT05333276 2023-07-27
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT01430572 2023-06-06
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02042989 2022-07-11
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05380882 2022-05-19
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT01548144 2021-09-13
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01021072 2021-02-16
A First in Man Study of MABp1 in Patients With Advanced Cancers
Janssen Research & Development, LLC
Phase 1 Completed
NCT01213238 2019-03-15
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01532011 2016-07-04
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01454804 2016-04-13
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00941499 2015-11-18
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00895362 2015-07-13
Erlotinib in Combination With Cetuximab
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02193672 2014-07-18
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01200004 2013-08-02
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01432119 2013-04-09
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00473720 2013-01-23
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Yale University
Phase 1 Completed
NCT01608139 2012-10-19
Study of Curcumin, Vorinostat, and Sorafenib
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00496444 2012-08-01
Azacytidine and Valproic Acid in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00903708 2012-07-30
LY2275796 in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed